1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Drugs In Development, 2022, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 31, 9, 1, 16 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 1 and 2 molecules, respectively.
Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Rhabdomyosarcoma - Overview
- Rhabdomyosarcoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Rhabdomyosarcoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rhabdomyosarcoma - Companies Involved in Therapeutics Development
- Rhabdomyosarcoma - Drug Profiles
- Rhabdomyosarcoma - Dormant Projects
- Rhabdomyosarcoma - Discontinued Products
- Rhabdomyosarcoma - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Rhabdomyosarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Rhabdomyosarcoma - Dormant Projects, 2022
- Rhabdomyosarcoma - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Rhabdomyosarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Abbisko Cayman Limited
- Actuate Therapeutics Inc
- Advenchen Laboratories LLC
- AI Therapeutics Inc
- Amgen Inc
- Aptadel Therapeutics SL
- Bayer AG
- Biogenera SpA
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Cellectar Biosciences Inc
- Edison Oncology Holding Corp
- Eisai Co Ltd
- Epizyme Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Galapagos NV
- Gate2Brain SL
- GenFleet Therapeutics (Shanghai) Inc
- GSK plc
- Hutchison MediPharma Ltd
- Immix BioPharma Inc
- ImmunityBio Inc
- Iproteos SL
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Lantern Pharma Inc
- MacroGenics Inc
- Mana Therapeutics Inc
- Mirati Therapeutics Inc
- NanoRED Biotechnology
- Novartis AG
- Ohara Pharmaceutical Co Ltd
- Oncoheroes Biosciences Inc
- Oncolys BioPharma Inc
- Onconova Therapeutics Inc
- Orgenesis Inc
- Orphelia Pharma SAS
- Peel Therapeutics Inc
- Pfizer Inc
- Pharma Mar SA
- Philogen SpA
- Provectus Biopharmaceuticals Inc
- Seneca Therapeutics Inc
- Shanghai Affinity Biomedical Technology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shepherd Therapeutics Inc
- Shionogi & Co Ltd
- Sorrento Therapeutics Inc
- Taiwan Liposome Co Ltd
- Tarveda Therapeutics Inc
- Tyra Biosciences Inc
- Veana Therapeutics LLC
